RxDoctor Payments Data

James Miller, MD

Gynecology · Madison, TNNPI 1225042740

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.4% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 31.1% of the total. Reporting peaked in 2022 at $441 and has fallen 56.1% since, to $193 in 2025.

$2,049in general payments, 2019–2025

Across 123 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$637
  • Astellas Pharma US Inc$200
  • Avion Pharmaceuticals$178
  • Mayne Pharma Commercial LLC$101
  • Millicent US Inc$91
  • Mylan Pharmaceuticals Inc.$73
  • plus $769 from 21 others

What the payments were for

  • Food & beverage$1,89492%
  • Education$1407%
  • Gifts$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,049 in reported general payments places this provider in the 80th percentile of 57 gynecology providers in Tennessee.

See all gynecology providers in Tennessee

Medicare billing

Part B allowed, 2024
$14,205
Medicare patients
75
Services billed
303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated89$34,555
Estradiol338$7,324
MyrbetriqMirabegron13$6,738
Estradiol (Twice Weekly)Estradiol39$3,917
DottiEstradiol20$2,424
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet17$1,260
Triamcinolone Acetonide88$936
Oxybutynin Chloride ErOxybutynin Chloride27$607
Escitalopram Oxalate20$307
Clobetasol Propionate17$302
Medroxyprogesterone Acetate17$207
AvianeLevonorgestrel/Ethin.Estradiol12$139
Citalopram HbrCitalopram Hydrobromide23$133
Sertraline Hcl12$82
Fluconazole14$69

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$46$34,55589 claims
Astellas Pharma US IncMyrbetriq$200$6,73813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 57 gynecology providers in Tennessee.

Other gynecology in Madison

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →